Amneal Concedes Validity of AstraZeneca’s Byetta Patents

AstraZeneca and Amneal have settled a patent infringement complaint where AstraZeneca accused Amneal of infringing on its patents for Byetta.

In a Monday filing in Delaware federal court, the drugmakers agreed on a proposed judgment that would admit the validity of eight patents held by AstraZeneca, and Amneal agreed not to manufacture, sell or distribute any products using those patents.

Under the settlement, all other claims and demands for relief by AstraZeneca are considered to be satisfied.

In July, FDA commissioner Scott Gottlieb met with representatives of several generics manufacturers, including Amneal, to discuss concerns that the makers of branded drugs have engaged in anticompetitive behavior to keep potential generic rivals off the market.